Clinical Trials Logo

Myasthenia Gravis clinical trials

View clinical trials related to Myasthenia Gravis.

Filter by:

NCT ID: NCT04431895 Recruiting - Clinical trials for Myasthenia Gravis, Generalized

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

Start date: June 11, 2020
Phase: Early Phase 1
Study type: Interventional

This is a 6 month study that will evaluate the efficacy of 5mg tofacitinib tablet taken twice a day in patients with refractory myasthenia gravis. Twenty adult participants will receive a four month treatment of tofacitinib followed by elution for one month.

NCT ID: NCT04226170 Recruiting - Myasthenia Gravis Clinical Trials

Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis

Start date: April 8, 2021
Phase: Phase 2
Study type: Interventional

This is a phase II, single center, randomized, double-blind, placebo-controlled, study in patients with a diagnosis of anti-AchR antibody positive myasthenia gravis.

NCT ID: NCT04224506 Recruiting - Myasthenia Gravis Clinical Trials

A Pilot Study to Explore the Role of Gut Flora in Myasthenia Gravis

Start date: March 2, 2020
Phase:
Study type: Observational

This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records.

NCT ID: NCT04202341 Recruiting - Clinical trials for Generalized Myasthenia Gravis

Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)

Start date: December 2, 2019
Phase:
Study type: Observational [Patient Registry]

Long-term, multicenter, multinational, observational, registry of patients with gMG that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT) such as eculizumab (Soliris®) and ravulizumab (Ultomiris®).

NCT ID: NCT04182984 Recruiting - Clinical trials for Ocular Myasthenia Gravis

TheRapeutic Effect of Different immunosuppressAnts on Non-Thymoma Ocular Myasthenia Gravis: a Real-world Study

TREAT-OMG
Start date: November 4, 2019
Phase:
Study type: Observational [Patient Registry]

This study collects the clinical data of new-onset ocular myasthenia gravis (OMG) patients, assesses outcomes and adverse effects of different treatment options, and evaluate risk factors of conversion to generalized MG(GMG).

NCT ID: NCT04146051 Recruiting - Clinical trials for Myasthenia Gravis, Generalized

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Start date: December 4, 2019
Phase: Phase 2
Study type: Interventional

This is a Phase IIb study to evaluate the safety and preliminary efficacy of Descartes-08 CAR T-cells in patients with Generalized Myasthenia Gravis

NCT ID: NCT04101578 Recruiting - Myasthenia Gravis Clinical Trials

Clinical Prognosis and Progression of Myasthenia Gravis Patients

Start date: February 8, 2017
Phase:
Study type: Observational

This study collects the clinical data of myasthenia gravis (MG) patients, assesses outcomes and adverse effects of different treatment regimens, and searches for risk factors of conversion to generalized MG.

NCT ID: NCT03914638 Recruiting - Myasthenia Gravis Clinical Trials

Beta-agonist Efficacy and Tolerability as Adjuvant Therapy in Myasthenia Gravis

BETA-MG
Start date: April 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This study examines the effect of adjuvant therapy with the oral beta-agonist Salbutamol in patients with generalized myasthenia gravis on stable standard of care having residual symptoms.

NCT ID: NCT03792659 Recruiting - Myasthenia Gravis Clinical Trials

The EXPLORE MG Registry for Myasthenia Gravis

Start date: March 30, 2016
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.

NCT ID: NCT03613272 Recruiting - Myasthenia Gravis Clinical Trials

The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum

Start date: July 1, 2018
Phase: N/A
Study type: Interventional

Extended thymectomy is the main treatment for thymoma and other anterior mediastinal diseases. Video-assisted thoracic surgery(VATS) plays an important role in the surgery of extended thymectomy. Now, VATS thymectomy through intercostal approach has been the commonly used minimally invasive surgical procedure for thymus surgery and is applied worldwide. But the intercostal approach may cause residue of thymus tissue and chronic pain. In 2013, doctor Marcin Zielin´ski form Poland reported a new technique of minimally invasive extended thymectomy performed through the VATS approach with double elevation of the sternum. And their early results proved this technique is probably the least invasive and the most complete technique of VATS thymectomy with excellent cosmetic results. Until now, doctor Jiang Fan form Shanghai Pulmonary Hospital has performed 50 cases extended thymectomy through the subxiphoid approach with double elevation of the sternum by VATS. This study is designed to compare the curative effect between this new method and traditional intercostal VATS.